Table 3.
Calculated rates of change per month across all assessed parameters while on dupilumab according to the linear models
| Initial TPS ≤ 4 | Initial TPS ≥ 5 | P value of difference | |
|---|---|---|---|
| TPS [RCpM] | 0.78 | 0.76 | 0.57 |
| SNOT-22 [RCpM] | 0.88 | 0.83 | 0.07 |
| Sniffin´ sticks [LCpM] | 0.54 | 0.75 | 0.08 |
| EQ-5D-3L [RCpM] | 0.99 | 0.99 | 0.67 |
| PHQ-2 [RCpM] | 0.83 | 0.85 | 0.29 |
| ACT [LCpM] | 0.21 | 0.19 | 0.8 |
| Mini AQLQ [LCpM] | 1.59 | 2.26 | 0.13 |
RCpM relative change per month, LCpM linear change per month, TPS total polyp score, SNOT-22 Sino Nasal Outcome Test 22, EQ5D-3L European Quality of Life Five Dimension 3 Level, PHQ-2 Patient Health Questionnaire 2, ACT Asthma Control Test, Mini AQLQ Mini Asthma Quality of Life Questionnaire